GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several life-threatening illnesses.

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is associated with improved clinical outcomes.

For adults with T2D and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs.